Studies in Treatment Phase & Follow-up
ABCSG 39 / Aphinity
A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer.
ABCSG 41 / OlympiA
A randomised, double-blind, parallel group, placebo-controlled multi-centre phase III study to assess the efficacy and safety of olaparib vs placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2-negative breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
ABCSG 42 / PALLAS
PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
ABCSG 43 / INSEMA
Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with stage I and II invasive breast cancer and breast-conserving surgery: a randomized prospective surgical trial
ABCSG 45
A prospective, open, randomized, phase II study of carboplatin/ olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status Coordinating Investigator: Christian Singer, Vienna Start of study 11/2019 Sample size: 90 (national) Sponsor: ABCSG Description and status: ABCSG 45 is an open, […]
ABCSG 48 / POSITIVE
A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (POSITIVE)
ABCSG 49 / POLAR
A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer
ABCSG 50 / BRCA-P
A randomized, double-blind, placebo-controlled, multi-center international phase III study to determine the preventive effect of Denosumab on breast cancer in women carrying a BRCA1 germline mutation
ABCSG 51 / AURORA
Aiming to understand the molecular aberrations in metastatic breast cancer: The AURORA program
ABCSG 56 / SASCIA
The ABCSG 56 / SASCIA is a GBG-sponsored, randomized, open-label, postneoadjuvant Phase III study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate, in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment.
ABCSG C08 / EXERCISE
A randomized, phase III trial of endurance exercise following adjuvant chemotherapy for colorectal cancer
ABCSG P02
A prospective randomized phase II trial of FOLFIRINOX alone versus FOLFIRINOX followed by radiochemotherapy in patients with locally advanced, primarily inoperable pancreatic cancer
Share on